Eyes On The Prize: Sen. Sanders’ Push For ‘Prize Fund’ Model For Pharma Ends With A Whimper

 
• By Michael McCaughan

Sen. Bernie Sanders has advocated for alternative models to pay for critical medicines in the US for most of his career. His best chance to advance the idea beyond the talking point stage appears to be ending with a request for a study.

Bernie Sanders at a Senate HELP Committee hearing
Sen. Bernie Sanders, right, has wanted to change biopharma innovation for years, but has not made much progress. • Source: Senate HELP Committee

More from Pricing Debate

More from Market Access